TNFRSF10B and breast carcinoma: A murine TRAIL-R2 monoclonal antibody demonstrated inhibition of tumour growth in a breast cancer xenograft model alone and in combination with chemotherapeutic agents and radiation (Buchsbaum et al, 2003).